Literature DB >> 28176205

Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.

Mohammad R Akbari1, Shiyu Zhang1, Deborah Cragun2, Ji-Hyun Lee2, Domenico Coppola2, John McLaughlin3, Harvey A Risch4, Barry Rosen5,6, Patricia Shaw7, Thomas A Sellers2, Joellen Schildkraut8, Steven A Narod9, Tuya Pal2.   

Abstract

A high proportion of ovarian cancers from women who carry germline mutations in mismatch repair (MMR) genes demonstrate microsatellite instability (MSI). The utility of pre-screening ovarian cancer specimens for MSI to identify potential patients for germline screening for MMR mutations is uncertain. 656 women with malignant ovarian cancer underwent both MSI testing and germline mutation testing for large rearrangements in three MMR genes, MLH1, MSH2 and MSH6. Germline DNA sequencing data for the same genes was available. Among the 656 women, only four (0.6%) carried a clearly pathogenic MMR mutation. All four cancers from patients with mutations had loss of two or more microsatellite markers (MSI-high). Eighty-four of 652 (13.0%) women without a mutation had MSI-high ovarian cancers. Using MSI-high as a prescreening criterion, the sensitivity of MSI testing to identify germline MMR gene mutations was 100% and the positive predictive value was 4.5%. Germline mutations in MLH1, MSH2 and MSH6 are rare among unselected cases of ovarian cancer. Patients with germline mutations often will have MSI-positive cancers and pre-screening of ovarian cancer specimens may be an efficient way of identifying patients with Lynch syndrome.

Entities:  

Keywords:  Microsatellite Instability; Ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 28176205     DOI: 10.1007/s10689-017-9973-1

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  23 in total

1.  Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.

Authors:  Tom Walsh; Silvia Casadei; Ming K Lee; Christopher C Pennil; Alex S Nord; Anne M Thornton; Wendy Roeb; Kathy J Agnew; Sunday M Stray; Anneka Wickramanayake; Barbara Norquist; Kathryn P Pennington; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

2.  Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.

Authors:  Steven A Narod; Victoria Sopik; Vasily Giannakeas
Journal:  Gynecol Oncol       Date:  2016-02-26       Impact factor: 5.482

3.  BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.

Authors:  S C Rubin; M A Blackwood; C Bandera; K Behbakht; I Benjamin; T R Rebbeck; J Boyd
Journal:  Am J Obstet Gynecol       Date:  1998-04       Impact factor: 8.661

4.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

5.  Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.

Authors:  Marietta E Kovacs; Janos Papp; Zoltan Szentirmay; Szabolcs Otto; Edith Olah
Journal:  Hum Mutat       Date:  2009-02       Impact factor: 4.878

Review 6.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

7.  Microsatellite instability in cancer of the proximal colon.

Authors:  S N Thibodeau; G Bren; D Schaid
Journal:  Science       Date:  1993-05-07       Impact factor: 47.728

8.  Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.

Authors:  P Peltomäki; R A Lothe; L A Aaltonen; L Pylkkänen; M Nyström-Lahti; R Seruca; L David; R Holm; D Ryberg; A Haugen
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

9.  The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer.

Authors:  Mercy Mvundura; Scott D Grosse; Heather Hampel; Glenn E Palomaki
Journal:  Genet Med       Date:  2010-02       Impact factor: 8.822

10.  Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer.

Authors:  T Pal; M R Akbari; P Sun; J-H Lee; J Fulp; Z Thompson; D Coppola; S Nicosia; T A Sellers; J McLaughlin; H A Risch; B Rosen; P Shaw; J Schildkraut; S A Narod
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

View more
  9 in total

Review 1.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

2.  Comparison of universal screening in major lynch-associated tumors: a systematic review of literature.

Authors:  George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis M Giardiello
Journal:  Fam Cancer       Date:  2021-01-11       Impact factor: 2.375

3.  Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer.

Authors:  Takashi Takeda; Kosuke Tsuji; Kouji Banno; Megumi Yanokura; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  J Gynecol Oncol       Date:  2018-01-30       Impact factor: 4.401

Review 4.  Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review.

Authors:  Tsukuru Amano; Tokuhiro Chano; Fumi Yoshino; Fuminori Kimura; Takashi Murakami
Journal:  Healthcare (Basel)       Date:  2019-07-30

Review 5.  How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies.

Authors:  Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

Review 6.  Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma.

Authors:  Tsukuru Amano; Atsushi Murakami; Takashi Murakami; Tokuhiro Chano
Journal:  Antioxidants (Basel)       Date:  2021-01-28

7.  The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.

Authors:  Amit Atwal; Tristan Snowsill; Marcus Cabrera Dandy; Thomas Krum; Claire Newton; Dafydd Gareth Evans; Emma J Crosbie; Neil A J Ryan
Journal:  Int J Cancer       Date:  2022-07-06       Impact factor: 7.316

Review 8.  Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and Ovarian).

Authors:  Camille Evrard; Jérôme Alexandre
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

9.  Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted.

Authors:  Patrick R Benusiglio; Florence Coulet
Journal:  Gynecol Oncol Rep       Date:  2018-10-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.